Cidara Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• Cidara Therapeutics Inc CDTX.OQ reported a quarterly adjusted loss of $1.66​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-2.28. The mean expectation of six analysts for the quarter was for a loss of $3.54 per share. Wall Street expected results to range from $-5.45 to $-1.47 per share.

• Reported revenue was zero​; analysts expected zero.

• Cidara Therapeutics Inc's reported EPS for the quarter was a loss of $1.66​.

• The company reported a quarterly loss of $23.48 million.

• Cidara Therapeutics Inc shares had fallen by 11.9% this quarter and lost 29.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 8.7% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Cidara Therapeutics Inc is $35.00

This summary was machine generated from LSEG data May 8 at 10:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)